Kin Li - Sihuan Pharmaceutical Joint Sec
| SHPHF Stock | | | USD 0.17 0.00 0.00% |
Insider
Kin Li is Joint Sec of Sihuan Pharmaceutical Holdings
| Age | 35 |
| Phone | 852 3628 3911 |
| Web | https://www.sihuanpharm.com |
Sihuan Pharmaceutical Management Efficiency
Sihuan Pharmaceutical's management efficiency ratios could be used to measure how well Sihuan Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Sihuan Pharmaceutical Holdings has accumulated 844.75
M in total debt with debt to equity ratio
(D/E) of 0.14, which may suggest the company is not taking enough advantage from borrowing. Sihuan Pharmaceutical has a current ratio of 2.38, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Sihuan Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Sihuan Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sihuan Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sihuan to invest in growth at high rates of return. When we think about Sihuan Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the Peoples Republic of China. The company was founded in 2001 and is based in Wanchai, Hong Kong. Sihuan Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 3896 people. Sihuan Pharmaceutical Holdings [SHPHF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Sihuan Pharmaceutical Leadership Team
Elected by the shareholders, the Sihuan Pharmaceutical's board of directors comprises two types of representatives: Sihuan Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sihuan. The board's role is to monitor Sihuan Pharmaceutical's management team and ensure that shareholders' interests are well served. Sihuan Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sihuan Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Weicheng Guo, Deputy Chairman, CEO and Member of Nomination Committee | |
| Xianhui Meng, Deputy General Manager of Sales and Marketing and Executive Director | |
| Yanling Chen, Joint Director | |
| Guili Miao, Chief CEO | |
| Kin Li, Joint Sec | |
| Fengsheng Che, Co-Founder, Executive Chairman and Member of Remuneration Committee | |
| Jionglong Zhang, Non-Executive Director | |
| Chengkon Shih, General Manager of Shandong Xuanzhu | |
| Feng Guo, Executive Director | |
Sihuan Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sihuan Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Sihuan Pink Sheet
Sihuan Pharmaceutical financial ratios help investors to determine whether Sihuan Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sihuan with respect to the benefits of owning Sihuan Pharmaceutical security.